Ocular Therapeutix sharpens focus with retina-centric rebrand
Ocular Therapeutix is making sure its corporate vision is 20/20 as it looks forward to phase 3 data on its eye disease drug candidate Axpaxli.
Ocular Therapeutix is making sure its corporate vision is 20/20 as it looks forward to phase 3 data on its eye disease drug candidate Axpaxli.
